Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Eli Lilly changes...

    Eli Lilly changes outcome goals in Alzheimer's drug study

    Written by savita thakur thakur Published On 2016-03-16T12:22:35+05:30  |  Updated On 16 March 2016 12:22 PM IST
    Eli Lilly changes outcome goals in Alzheimers drug study
    Eli Lilly said on Tuesday that it has changed the outcome goals for a late-stage patient study of its closely watched experimental drug for Alzheimer's disease, Solanezumab.

    The Expedition3 trial had two primary outcome measures: changes in participants' cognition and their daily function. Now cognition will remain a primary outcome measure, while function will be a secondary measure of the drug's effectiveness.

    Eli Lilly and Co., based in Indianapolis, said in a statement that it made the change because "emerging scientific evidence supports the idea that cognitive decline precedes and predicts functional decline" in Alzheimer's patients.

    Late-stage studies usually are the last ones before drug developers seek regulatory approval.

    Investors, apparently nervous about the news after a few similar Alzheimer's drugs that other drugmakers were developing also failed in testing, drove shares down $2.67, or 3.6 percent, to $71.24.

    Credit Suisse analyst Dr. Vamil Divan wrote to investors that the news adds to uncertainty over "what was already a high-risk program."

    He added that he understands the rationale for making the change now and "for why the study should ultimately be positive." Divan wrote that he still sees a "path for the drug making it to the market."

    If that happened, solanezumab would definitely generate billions in annual sales. That is because existing Alzheimer's drugs only alleviate symptoms temporarily, leaving doctors little to offer to help patients and their caregivers.

    Solanuzumab works by clearing a substance called amyloid beta from the brain before it clumps together in the plaques that are the hallmark of the mind-robbing disorder. It's being studied to treat patients with very early Alzheimer's in hopes it would prevent that damage.

    About 5.3 million Americans, most of them over 65, have Alzheimer's disease, which is the sixth-leading cause of death in the U.S., according to the Alzheimer's Association.

    The number of Alzheimer's patients worldwide is now estimated at 47 million and is expected to jump to nearly 132 million by 2050.

    Source: AP
    Alzheimer drugAlzheimer's diseaseDr. Vamil DivanEli Lillysolanezumab

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok